References
- Haraoui B. Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum. 2005;34:7–11.
- Nurmohamed MT, Dijkmans BA. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and bio-logic agents in rheumatoid arthritis. Drugs. 2005;65:661–94.
- Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully anti-tumour necrosis factor-a monoclonal antibody, and concomitant standard anti-rheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003;30:2563–71.
- Seymour HE, Worsley A, Smith JM, Thomas SHL. Anti-TNF agents for rheumatoid arthritis. Br J Clin Pharmacol. 2001;51: 201–8.
- Doulton TW, Tucker B, Reardon J, Velasco N. Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulo- nephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis. Clin Nephrol. 2004;62:234–8.
- Stokes MB, Foster K, Markowitz GS, Ebrahimi F, Hines W, Kaufman D, et al. Development of glomerulonephritis during anti-TNF-a therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005;20:1400–6.
- Ashok D, Dubey S, Tomlinson I. C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with inf-liximab. Clin Rheumatol. 2008;27:261–4.
- Simms R, Kipgen D, Dahill S, Marshall D, Rodger RS. ANCA-associated renal vasculitis following anti-tumor necrosis factor alpha therapy. Am J Kidney Dis. 2008;51:11–4.
- Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
- Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, et al. A randomised trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoanti-body. N Engl J Med. 2003;349:36–44.
- Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis. 2003;41:776–84.
- Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med. 2005;143:621–31.
- Lamprecht P, Voswinkel J, Lilienthal T, Nolle B, Heller M, Gross WL, et al. Effectiveness of TNF-a blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology. 2002;41: 1303–7.
- Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C, et al. Efficacy of the anti-TNF-a antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology. 2002;41: 1126–32.
- Booth AD, Jefferson H.T, Ayliffe W, Andrews PA, Jayne DR. Safety and efficacy of TNF alpha blockade in relapsing vasculitis. Ann Rheum Dis. 2002;61:559.
- Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum. 2001;44:1149–54.
- The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005;352:351–61.
- Kamesh L, Harper L, Savage COS. ANCA-positive vasculitis. J Am Soc Nephrol. 2002;13:1953–60.
- Hoffman GS, Specks U. Antineutrophil cytoplasmic antibodies. Arthritis Rheum. 1998;41:1521–37.
- Guillevin L, Mouthon L. Tumour necrosis factor-a blockade and the risk of vasculitis. J Rheumatol. 2004;31:1885–7.
- Little MA, Bhangal G, Smyth C, Nakada MT, Cook HT, Nour-shargh S, et al. Therapeutic effect of anti-TNF-a antibodies in an experimental model of anti-neutrophil cytoplasm antibody-asso-ciated systemic vasculitis. J Am Soc Nephrol. 2006;17:160–9.